Oncology
A checkpoint combination extends survival in advanced melanoma
Five-year data suggest durable responses for a third of patients, but toxicity remains the trade-off.
Clara Whitfield · 1 November 2026
Clinical Trials Hub: clinical trial and medical research news
NeurologyAmyloid drugs, a second look
New data reopen the debate over who benefits from anti-amyloid antibodies.
Clara Whitfield · 31 October 2026
Rare DiseasesOne dose, a lifetime: the economics of gene therapy
Curative treatments are arriving faster than payers can price them.
Clara Whitfield · 30 October 2026
CardiologyGLP-1 drugs and the heart: what the outcomes trials show
Beyond weight loss, cardiovascular benefits are reshaping prescribing.
Clara Whitfield · 29 October 2026
Latest
The Briefing
Trial results that matter, every Friday.
One email. The week's readouts, approvals and research, explained without hype.
Trial News
More →
Trial NewsSeven phase 3 readouts to watch this quarter
From obesity to Alzheimer's, the trials that could move markets.
Clara Whitfield · 26 October 2026
Oncology
More →
OncologyTarlatamab extends small cell lung cancer survival by 8 months
Adding tarlatamab to durvalumab maintenance raised median survival from 12.7 to 21.1 months in extensive-stage small cell lung cancer, with mostly mild immune reactions.
24 October 2026
OncologyDrugs around bladder surgery help people who can't have cisplatin
In the VOLGA trial, durvalumab plus enfortumab vedotin around bladder removal lifted two-year survival from 69% to 78% for people who couldn't or wouldn't have cisplatin.
24 October 2026
OncologyA personalised mRNA vaccine cuts melanoma relapse after surgery
A vaccine built from each patient's own tumour, given with pembrolizumab, kept 82% of people relapse-free at two years against 70% on pembrolizumab alone.
24 October 2026
OncologyBowel cancer immunotherapy pair keeps 3 in 4 alive at five years
Final CheckMate 8HW data show nivolumab plus ipilimumab left 77% of people with MSI-high metastatic bowel cancer alive at five years, against 46% on chemotherapy.
24 October 2026
Rare Diseases
More →
Rare DiseasesSickle cell tablet lifts blood counts but pain crises barely move
In the Lancet-published RISE UP trial, mitapivat raised haemoglobin in 41% of people with sickle cell disease against 3% on placebo, but pain crises didn't fall significantly.
22 October 2026
Rare DiseasesWeekly atacicept keeps kidney function steady in IgA nephropathy
In the ORIGIN 3 trial, people with IgA nephropathy on weekly atacicept lost almost no kidney function over two years, against about 5.6 eGFR units a year on placebo.
22 October 2026
Rare DiseasesDaily pill gives people with sun-induced pain more time outdoors
Phase 3 APOLLO results show bitopertin added about 12 pain-free hours in light each month and cut painful reactions by 71% in erythropoietic protoporphyria, a rare inherited condition.
19 October 2026
Rare DiseasesOne-off Huntington's gene therapy still slows decline at 4 years
Four-year data on uniQure's AMT-130 show slower loss of daily function at the high dose, though the main rating scale result was no longer statistically significant.
29 September 2026
Cardiology
More →CardiologyGLP-1 drugs and the heart: what the outcomes trials show
Beyond weight loss, cardiovascular benefits are reshaping prescribing.
Clara Whitfield · 29 October 2026
Neurology
More →NeurologyAmyloid drugs, a second look
New data reopen the debate over who benefits from anti-amyloid antibodies.
Clara Whitfield · 31 October 2026
Drug Approvals
More →
Drug ApprovalsThe accelerated approval pathway, reformed
New rules demand confirmatory trials be underway before approval.
Clara Whitfield · 28 October 2026
Patient Guides
More →
Patient GuidesHow to find a clinical trial that fits you
A practical guide to registries, eligibility and the questions to ask.
Clara Whitfield · 27 October 2026
Industry & Regulation
More →
Industry & RegulationNew rules on trial diversity take effect
Sponsors must now submit diversity action plans for pivotal studies.
Clara Whitfield · 25 October 2026